{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:34:10Z","timestamp":1791038050739,"version":"4.1.0"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Human immunodeficiency virus (HIV) infection is now recognized as a chronic illness. Although the success of highly active antiretroviral therapy is beyond question, several issues still persist. Since the drugs cannot eradicate the virus, cure is not yet possible, and patients have to maintain a lifelong adherence with the risk of toxic effects, drug-drug interactions and drug resistance. A clear understanding of the viral replication and its interaction with host cell factors has led to the development of a large number of effective antiretroviral drugs (ARVs). New drugs in the existing class such as apricitabine, elvucitabine and etravirine have shown promising results against HIV isolates resistant to first line drugs. These drugs have offered a new choice for patients with drug resistant disease. However, the impact of their long term use on safety is yet to be assessed. Novel drugs with unique mechanism of action such as CD4 receptor attachment inhibitors, maturation inhibitors, pharmacokinetic enhancers, capsid assembly inhibitors and lens epithelium derived growth factor inhibitors are still under development. Currently, ARVs, especially tenofovir and emtricitabine, are also being evaluated for prevention of sexual transmission of HIV-1. The initial results of an HIV prevention trial network are encouraging and have recommended the use of ARVs for pre-exposure prophylaxis. Thus, ARVs form the key component of HIV prevention and treatment strategy. This article discusses the challenges associated with HIV-1 treatment and updates several major advances in the development of ARVs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0253-7613.96296","type":"journal-article","created":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T14:28:31Z","timestamp":1337264911000},"page":"288-298","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":59,"title":["Antiretroviral drugs"],"prefix":"10.4103","volume":"44","author":[{"given":"Mira","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetha","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. K.","family":"Dikshit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20260529","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11904-011-0076-6","article-title":"Antiretroviral therapy: A key component of a comprehensive HIV prevention strategy","volume":"8","author":"Hull","year":"2011","journal-title":"Curr HIV\/AIDS Rep"},{"key":"R2-2-20260529","first-page":"138","article-title":"Update of the drug resistance mutations in HIV-1","volume":"16","author":"Johnson","year":"2008","journal-title":"Top HIV Med"},{"key":"R3-2-20260529","first-page":"165","article-title":"Retroviral reverse transcriptases: Error frequencies and mutagenesis","volume":"176","author":"Williams","year":"1992","journal-title":"Curr Top Microbiol Immunol"},{"key":"R4-2-20260529","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","article-title":"HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time","volume":"271","author":"Perelson","year":"1996","journal-title":"Science"},{"key":"R5-2-20260529","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"key":"R6-2-20260529","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells","volume":"9","author":"Siliciano","year":"2003","journal-title":"Nat Med"},{"key":"R7-2-20260529","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2174\/157016206776055084","article-title":"HAART-persistent HIV-1 latent reservoirs: Their origin, mechanisms of stability and potential strategies for eradication","volume":"4","author":"Kulkosky","year":"2006","journal-title":"Curr HIV Res"},{"key":"R8-2-20260529","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003495-200868010-00004","article-title":"Antiretroviral therapy: Optimal sequencing of therapy to avoid resistance","volume":"68","author":"Martinez-Cajas","year":"2008","journal-title":"Drugs"},{"key":"R9-2-20260529","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"R10-2-20260529","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJMoa022048","article-title":"Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection","volume":"348","author":"Bozzette","year":"2003","journal-title":"N Engl J Med"},{"key":"R12-2-20260529","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2710.2003.00541.x","article-title":"Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care","volume":"29","author":"De Maat","year":"2004","journal-title":"J Clin Pharm Ther"},{"key":"R13-2-20260529","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/clpt.2008.168","article-title":"Dose \u2013 response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure","volume":"85","author":"Mathias","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R14-2-20260529","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1468-1293.2008.00610.x","article-title":"Potential health risks of complementary alternative medicines in HIV patients","volume":"9","author":"Ladenheim","year":"2008","journal-title":"HIV Med"},{"key":"R15-2-20260529","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection","volume":"133","author":"Paterson","year":"2000","journal-title":"Ann Intern Med"},{"key":"R16-2-20260529","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2147\/CIA.S2086","article-title":"HIV infection in the elderly","volume":"3","author":"Nguyen","year":"2008","journal-title":"Clin Interv Aging"},{"key":"R17-2-20260529","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/nm0703-853","article-title":"HIV-1 pathogenesis","volume":"9","author":"Stevenson","year":"2003","journal-title":"Nat Med"},{"key":"R19-2-20260529","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.qai.0000168882.67942.3f","article-title":"The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: Implications for once-daily dosing","volume":"39","author":"Back","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R21-2-20260529","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"key":"R22-2-20260529","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1097\/01.meg.0000243877.17444.5e","article-title":"Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen","volume":"18","author":"Santos","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R24-2-20260529","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.coph.2004.06.001","article-title":"New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections","volume":"4","author":"Otto","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"R25-2-20260529","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/AAC.50.2.625-631.2006","article-title":"In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection","volume":"50","author":"Gu","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-2-20260529","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3851\/IMP1514","article-title":"Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double blind placebo controlled study in HIV-1 infected individuals","volume":"15","author":"Murphy","year":"2010","journal-title":"Antivir Ther"},{"key":"R30-2-20260529","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1089\/apc.2007.0020","article-title":"Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine","volume":"21","author":"Crane","year":"2007","journal-title":"AIDS Patient Care STDS"},{"key":"R31-2-20260529","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1128\/JVI.01154-07","article-title":"Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors","volume":"82","author":"Hachiya","year":"2008","journal-title":"J Virol"},{"key":"R32-2-20260529","doi-asserted-by":"crossref","first-page":"12773","DOI":"10.1128\/JVI.79.20.12773-12782.2005","article-title":"TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments","volume":"79","author":"Vingerhoets","year":"2005","journal-title":"J Virol"},{"key":"R33-2-20260529","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/jac\/dkm372","article-title":"Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors","volume":"60","author":"Poveda","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R36-2-20260529","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/ajhp\/61.13.1365","article-title":"Atazanavir: A new protease inhibitor to treat HIV infection","volume":"61","author":"Musial","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"R37-2-20260529","first-page":"174","article-title":"Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia","volume":"39","author":"Mobius","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R38-2-20260529","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00126334-200301010-00004","article-title":"Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects","volume":"32","author":"Sanne","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R39-2-20260529","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/00002030-200009080-00009","article-title":"Tipranavir inhibits broadly protease inhibitor resistant HIV-1 clinical samples","volume":"14","author":"Larder","year":"2000","journal-title":"AIDS"},{"key":"R40-2-20260529","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(06)69154-X","article-title":"Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment- experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in Multi-drug Resistant Patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials","volume":"368","author":"Hicks","year":"2006","journal-title":"Lancet"},{"key":"R41-2-20260529","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2165\/00003495-200363150-00009","article-title":"Tipranavir","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs"},{"key":"R42-2-20260529","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"R43-2-20260529","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/jmv.21034","article-title":"Overcoming resistance to existing therapies in HIV-infected patients: The role of new antiretroviral drugs","volume":"80","author":"Perno","year":"2008","journal-title":"J Med Virol"},{"key":"R44-2-20260529","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/QAD.0b013e32830285fb","article-title":"Efficacy and safety of once-daily darunavir\/ritonavir versus lopinavir\/ritonavir in treatment-naive HIV-1-infected patients at week 48","volume":"22","author":"Ortiz","year":"2008","journal-title":"AIDS"},{"key":"R45-2-20260529","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1186\/1479-5876-9-S1-S9","article-title":"Clinical use of CCR5 inhibitors in HIV and beyond","volume":"9","author":"Gilliam","year":"2011","journal-title":"J Transl Med"},{"key":"R46-2-20260529","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/QAI.0b013e3181ee3d82","article-title":"Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2","volume":"55","author":"Hardy","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R47-2-20260529","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated patients with R5 HIV-1 infection","volume":"359","author":"Gulick","year":"2008","journal-title":"N Engl J Med"},{"key":"R48-2-20260529","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1086\/650697","article-title":"Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 Infection","volume":"201","author":"Cooper","year":"2010","journal-title":"J Infect Dis"},{"key":"R49-2-20260529","first-page":"110","article-title":"Emerging resistance profiles of newly approved antiretroviral drugs","volume":"16","author":"Daar","year":"2008","journal-title":"Top HIV Med"},{"key":"R50-2-20260529","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/511035","article-title":"Chemokine co-receptor tropism among antiretroviral-experienced patients screening for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trials Group A5211","volume":"44","author":"Wilkin","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R51-2-20260529","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1086\/592169","article-title":"Antiviral activity of single dose PRO140, a CCR5 monoclonal antibody, in HIV infected patients","volume":"198","author":"Jacobson","year":"2008","journal-title":"J Infect Dis"},{"key":"R52-2-20260529","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1128\/AAC.00699-06","article-title":"Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1","volume":"50","author":"Murga","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R53-2-20260529","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1128\/AAC.00086-10","article-title":"Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults","volume":"54","author":"Jacobson","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R55-2-20260529","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, a HIV-1 fusion inhibitor, for drug resistance HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N Engl J Med"},{"key":"R56-2-20260529","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/TCRM.S1962","article-title":"Enfuvirtide antiretroviral therapy in HIV-1 infection","volume":"4","author":"Kitchen","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"R57-2-20260529","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/135965350601100110","article-title":"Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral naive, HIV-infected patients","volume":"11","author":"Molto","year":"2006","journal-title":"Antivir Ther"},{"key":"R58-2-20260529","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1074\/jbc.M110.199323","article-title":"In vitro selection and charecterization of HIV-1 variants with increased resistance to sifuviritde, a novel HIV-1 fusion inhibitor","volume":"286","author":"Liu","year":"2011","journal-title":"J Biol Chem"},{"key":"R59-2-20260529","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/427993","article-title":"T-1249 Retains Potent Antiretroviral Activity in Patients Who Had Experienced Virological Failure while on an Enfuvirtide-Containing Treatment Regimen","volume":"191","author":"Lalezari","year":"2005","journal-title":"J Infect Dis"},{"key":"R60-2-20260529","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2147\/TCRM.S2268","article-title":"Raltegravir: First in class HIV integrase inhibitor","volume":"4","author":"Temesgen","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"R61-2-20260529","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/QAI.0b013e3181b064b0","article-title":"Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment na\u00efve patients with HIV-1 infection","volume":"52","author":"Markowitz","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R62-2-20260529","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","article-title":"Switch to a raltegravir based regimen versus continuation of a lopinavir-ritonavir based regimen in stable HIV infected patients with suppressed viremia (SWITCHMRK 1 and 2): Two multicentre, double blind, randomized controlled trials","volume":"375","author":"Eron","year":"2010","journal-title":"Lancet"},{"key":"R63-2-20260529","first-page":"18","article-title":"Integrase strand transfer inhibitors as potential anti-HIV agent","volume":"2","author":"Yasmin","year":"2011","journal-title":"GERF Bull Biosci"},{"key":"R64-2-20260529","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1086\/650698","article-title":"Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial","volume":"201","author":"Zolopa","year":"2010","journal-title":"J Infect Dis"},{"key":"R65-2-20260529","first-page":"65","article-title":"Patterns with resistance development with integrase inhibitors in HIV","volume":"4","author":"Mbisa","year":"2011","journal-title":"Infect Drug Resist"},{"key":"R66-2-20260529","first-page":"203","article-title":"GSK-1349572, a novel integrase inhibitor for the treatment of HIV infection","volume":"11","author":"Vandekerckhove","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"R67-2-20260529","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/clpt.2009.228","article-title":"Pharmacokinetics and pharmacodynamics of GS-9350: A novel pharmacokinetic enhancer without anti-HIV activity","volume":"87","author":"Mathias","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R70-2-20260529","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/jac\/dkq261","article-title":"Ibalizumab: An anti-CD4 monoclonal antibody for the treatment of HIV-1 infetcion","volume":"65","author":"Bruno","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R71-2-20260529","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/AAC.00942-08","article-title":"Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults","volume":"53","author":"Jacobson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R72-2-20260529","first-page":"162","article-title":"Maturation Inhibitors: A New therapeutic class targets the virus structure","volume":"9","author":"Salzwedel","year":"2007","journal-title":"AIDS Rev"},{"key":"R73-2-20260529","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1073\/pnas.0914142107","article-title":"Lens epithelium-derived growth factor fusion proteins redirect HIV-1 DNA integration","volume":"107","author":"Ferrisa","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R74-2-20260529","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nchembio.370","article-title":"Rational design of small-molecule inhibitors of the LEDGF\/p75-integrase interaction and HIV replication","volume":"6","author":"Christ","year":"2010","journal-title":"Nat Chem Biol"},{"key":"R75-2-20260529","doi-asserted-by":"crossref","first-page":"e1001220","DOI":"10.1371\/journal.ppat.1001220","article-title":"HIV capsid is a tractable target for small molecule therapeutic intervention","volume":"6","author":"Blair","year":"2010","journal-title":"Plos Pathog"},{"key":"R76-2-20260529","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.antiviral.2009.10.013","article-title":"Development of topical microbicides to prevent the sexual transmission of HIV","volume":"85","author":"Buckheit","year":"2010","journal-title":"Antiviral Res"},{"key":"R77-2-20260529","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(07)60202-5","article-title":"Microbicide drug candidates to prevent HIV infection","volume":"369","author":"Balzarini","year":"2007","journal-title":"Lancet"},{"key":"R78-2-20260529","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Abdool Karim","year":"2010","journal-title":"Science"},{"key":"R79-2-20260529","first-page":"1","article-title":"Pre-exposure prophylaxis of HIV","volume":"32","author":"Naswa","year":"2011","journal-title":"Indian J Sex Transm Dis"},{"key":"R80-2-20260529","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1128\/AAC.01156-08","article-title":"Inhibition of Human Immunodeficiency Virus Type 1 Infection by the Candidate Microbicide Dapivirine, a Nonnucleoside Reverse Transcriptase Inhibitor","volume":"53","author":"Fletcher","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R81-2-20260529","first-page":"9","article-title":"Current progress in the development of a prophylactic vaccine for HIV-1","volume":"5","author":"Gamble","year":"2010","journal-title":"Drug Des Devel Ther"},{"key":"R82-2-20260529","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev.med.042508.093728","article-title":"HIV-1 vaccine development after STEP","volume":"61","author":"Barouch","year":"2010","journal-title":"Annu Rev Med"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363791-201244030-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:13:40Z","timestamp":1787843620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363791-201244030-00002"}},"subtitle":["Critical issues and recent advances"],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.4103\/0253-7613.96296","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}